| Study Name | Description | Trial Category | Trial SubCategory |
|---|---|---|---|
| Abbott Aveir dual chamber pacemaker | The objective for this study is to confirm the safety and effectiveness of the Aveir LP (Leadless Pacemaker) System in a subject population indicated for a dual chamber pacemaker. | Heart & Vascular | Cardiac Arrhythmia |
| Abbott Aveir dual chamber pacemaker | The objective for this study is to confirm the safety and effectiveness of the Aveir LP (Leadless Pacemaker) System in a subject population indicated for a dual chamber pacemaker. | Heart & Vascular | Cardiac Arrhythmia |
| Amgen Registry | Study of Lipoprotein(a) Levels in Patients With History of Atherosclerotic Cardiovascular Disease (ASCVD) | Heart & Vascular | Cardiovascular Disease |
| Arrhythmia Detection After Myocardial Infarction (AID-MI) | This study will evaluate the use of an insertable cardiac monitor in patients following an acute myocardial infarction (heart attack) to determine if cardiac monitoring results in more rhythm-related findings that change management compared to standard of care post heart attack management in patients who do not receive the insertable cardiac monitor. | Heart & Vascular | Cardiac Arrhythmia |
| Change AF | Pragmatic Randomized Clinical Trial of Early Dronedarone versus Usual Care to Change and Improve Outcomes in Persons with First-Detected Atrial Fibrillation (CHANGE AFib) | Heart & Vascular | Cardiac Arrhythmia |
| CREST 2 LOE | Long-Term Observational Extension of Participants in the CREST-2 Randomized Clinical Trial (C2LOE) | Heart & Vascular | Other - Carotid Stenosis |
| Faraday STEMI drug | The purpose of this study is to evaluate the efficacy and safety of the study drug vs placebo in subjects with an anterior ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI). | Heart & Vascular | Heart Failure |
| Kintor Covid | The objective for this study is to evaluate the safety and efficacy of the drug Proxalutamide in hospitalized adults diagnosed with COVID-19. | Pulmonary | Respiratory |
| Optimizer PAS | The Impulse Dynamics OPTIMIZER Smart Pre-Market Application (PMA) clinical data confirmed that CCM therapy delivered with the Optimizer meaningfully improved health outcomes in patients with NYHA class III heart failure symptoms and left ventricular ejection fraction of 25-45%. CCM has shown significant improvements in quality of life measures, with an average improvement of >11 points in MLHWFQ incremental to the improvement of a randomized control group with no device. Six minute hall walk and functional class also showed improvements in the PMA data. The post-approval study (PAS) protocol has been designed to evaluate long term safety and efficacy of the OPTIMIZER Smart in a real-world setting. | Heart & Vascular | Heart Failure |
| Real AF Registry | Real-world Experience of Catheter Ablation for the Treatment of Symptomatic Paroxysmal and Persistent Atrial Fibrillation Using Novel Contact Force Technologies: REAL AF Registry | Heart & Vascular | Atrial Fibrillation |
| V-Inception | A randomized, controlled, multicenter, open-label trial comparing a hospital post-discharge care pathway involving aggressive LDL-C management that includes inclisiran with usual care versus usual care alone in patients with a recent acute coronary syndrome(VICTORION-INCEPTION) | Heart & Vascular | Lipid Management |
| CanGaroo | The objective of this study is to explore the subject clinical profiles, procedural details and post-implant outcomes of patients who receive either the CanGaroo ECM Envelope or no envelope at the time of initial implantation. | Heart & Vascular | Atrial Fibrillation |
| HSY244 | The objective for this study is to evaluate the efficacy, pharmacokinetics, safety and tolerability of HSY244 to restore sinus rhythm in patients with Atrial Fibrillation (AF). The study subjects have current ongoing episodes of AF for more than 6 hours and less than 30 days. | Heart & Vascular | Atrial Fibrillation |
| A011202 | A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy https://clinicaltrials.gov/ct2/show/NCT03797326?term=NCT03797326&draw=2&rank=1 | Cancer | Breast |
| A011801 | The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib https://clinicaltrials.gov/ct2/show/NCT04457596?term=NCT04457596&draw=2&rank=1 | Cancer | Breast |
| A221805 | Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study https://clinicaltrials.gov/ct2/show/NCT04137107?term=NCT04137107&draw=2&rank=1 | Cancer | Gastrointestinal |
| ACCRU-BR-1801 | A Phase II Trial of Abemaciclib and T-DM1 in Women and Men with HER2 positive Advanced or Metastatic Breast Cancer Who Progressed on Treatment with a Taxane, Trastuzumab and Pertuzumab https://clinicaltrials.gov/ct2/show/NCT04351230?term=NCT04351230&draw=2&rank=1 | Cancer | Breast |
| EA2176 | A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients https://clinicaltrials.gov/ct2/show/NCT04444921?term=NCT04444921&draw=2&rank=1 | Cancer | Gastrointestinal |
| EA2187 | A Phase 2 Study of Penvonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma https://clinicaltrials.gov/ct2/show/NCT04175912?term=NCT04175912&draw=2&rank=1 | Cancer | Gastrointestinal |
| NRG-GY009 | Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum https://clinicaltrials.gov/ct2/show/NCT03797326?term=NCT03797326&draw=2&rank=1 | Cancer | Other |
| S1613 | A randomized Phase II study of Trastuzumab and Pertuzumab (TP) compared to Cetuximab and Irinotecan (Cetiri) in advanced/metastatic colorectal cancer (MCRC) with Her-2 amplification https://clinicaltrials.gov/ct2/show/NCT03365882?term=S1613&draw=2&rank=1 | Cancer | Other |
| S1925 | S1925 Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study https://clinicaltrials.gov/ct2/show/NCT04269902?term=NCT04269902&draw=2&rank=1 | Cancer | Hematology |
| A021703 | Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS) | Cancer | Gastrointestinal |
| A031501 | Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation | Cancer | Bladder/Urothelial |
| A031803 | Phase II Trial of Intravesical Gemcitabine and MK-3475 (pembrolizumab) in the Treatment of Patients with BCG-Unresponseve Non-Muscle Invasive Bladder Cancer | Cancer | Bladder |
| A041702 | Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age) | Cancer | Hematology |
| A061202 | A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib VS. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy | Cancer | Multiple Myeloma |
| AALL08B1 | Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | Childhood Cancers | Leukemia |
| AALL0932 | Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) | Childhood Cancers | Leukemia |
| AALL1231 | A Phase lll Randomized Trial Investigating Bortezomib (NSC#681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) | Childhood Cancers | Leukemia |
Unsupported Browser! This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.